The Relationship Between Epicardial Fat Tissue and Cardiac Function in HFpEF Patients

NCT05068934 | Completed

• 1 other identifier: 2020-09
• Study Type: observational
• Target: 1,083
• Locations: 1 country
• Sites: 1

Brief Summary

Heart failure with preserved ejection fraction (HFpEF) refers to a group of symptoms and signs of heart failure, normal or near-normal left ventricular systolic function (EF\>50%), and ventricular muscle diastolic dysfunction and A clinical syndrome characterized by decreased compliance and increased stiffness. The pathogenesis of HFpEF is related to impaired lipid metabolism and inflammation. Epicardial adipose tissue (Epicardial Adipose tissue, EAT) is a kind of visceral adipose tissue. Related studies have shown that extracardiac Membrane fat is related to inflammation markers, cardiometabolic risk and cardiovascular disease.However, there is still no research investigating the the relationship between epicardial fat thickness and Cardiac Function in HFpEF patients.

Conditions

Heart Failure With Preserved Ejection Fraction

Keywords

Epicardial Adipose tissue; Cardiac Function

Outcome Measures

Primary Outcomes (3)

• Epicardial Fat Tissue

  Epicardial Fat Tissue by cardiac color Doppler ultrasound

  On admission

• Cardiac Function

  Left ventricular diastolic function and right ventricular systolic function by cardiac color Doppler ultrasound

  On admission

• Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death

  Composite Endpoint of Worsening Heart Failure Event and Cardiovascular Death

  From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years

Secondary Outcomes (3)

• Worsening HF Event

  From date of discharge until the date of first worsening HF event or date of death, whichever came first, assessed up to 5 years

• CV Death

  From date of discharge until the date of death, whichever came first, assessed up to 10 years

• All-cause Death

  From date of discharge until the date of death, whichever came first, assessed up to 10 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Heart failure patients with preserved ejection fraction (HFpEF)

You may qualify if:

• Adult aged \>=18years old;
• Diagnosed with HFpEF.
• Diagnostic criteria including:
• left ventricular ejection fraction ≥50%；
• with the symptoms and/or signs of heart failure；
• BNP≥35 pg/mL and/or NTproBNP≥125 pg/mL；
• at least one additional criterion: relevant structural heart disease(LVH and/or LAE) or diastolic dysfunction

You may not qualify if:

• LVEF less than 45% at any time;
• Severe liver failure;
• Primary pulmonary hypertension;
• Age \<18 years old.

Sponsors & Collaborators

• Dongying Zhang: lead

Study Sites (1)

The First Affiliated Hospital of Chongqing Medical University

Chongqing, China

Location

Study Officials

• Dongying Zhang, doctor

  First Affiliated Hospital of Chongqing Medical University

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Dongying Zhang

Study Record Dates

• First Submitted: September 26, 2021
• First Posted: October 6, 2021
• Study Start: October 12, 2020
• Primary Completion: December 10, 2025
• Study Completion: December 15, 2025
• Last Updated: January 6, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)